Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Recruiting 5Terminated 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Colorectal Neoplasms 3Skin Neoplasms 2Melanoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Turcot syndrome 1Solid Tumors 1Solid Tumor, Adult 1Rectal Neoplasms 1Radiation Pneumonitis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Motor Activity 1Lung Neoplasms 1Locally Advanced Esophageal Squamous Cell Carcinoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

pembrolizumab 34Specimen Handling 18Paclitaxel 16Magnetic Resonance Spectroscopy 15Carboplatin 14Biopsy 14Nivolumab 13Ipilimumab 12Gemcitabine 10Irinotecan 9Radiosurgery 8atezolizumab 7abemaciclib 7Radiation 7Pemetrexed 7Cisplatin 7Capecitabine 7130-nm albumin-bound paclitaxel 7trastuzumab deruxtecan 6olaparib 6durvalumab 6avelumab 6Docetaxel 6osimertinib 5adagrasib 5Trastuzumab 5Fulvestrant 5Cetuximab 5Albumin-Bound Paclitaxel 5palbociclib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasm Metastasis × Immune Checkpoint Inhibitors × Clear all
NCT06076135 2025-06-15

ILDR-01

Shantou University Medical College

Phase 2 Active not recruiting
16 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡